摘要
目的:探讨血清抗心磷脂抗体(anticardiolipin antibody,ACL)、抗β2-糖蛋白I抗体(anti-beta2-glycoproteinI antibody,抗β2-GPI抗体)和狼疮抗凝物(lupus anticoagulant antibody,LAC)联合检测对复发性流产(recurrent spontaneous abortion,RSA)的预测意义。方法:选取85例RSA患者为实验组,50例正常经产妇作为对照组,检测两组血清ACL、抗β2-GP1抗体和LAC水平。结果:RSA组ACL阳性率为27.06%(23/85),而对照组为8%(4/50),差异有统计学意义(P<0.01);抗β2-GPI抗体阳性率为21.18%(18/85),而对照组2%(1/50),差异有统计学意义(P<0.01);LAC阳性率为21.18%(18/85),而对照组为6%(3/50),差异有统计学意义(P<0.05)。在确诊的40例抗磷脂抗体综合症患者中,ACL或抗β2-GPI抗体阳性率为95.00%(38/40),和ACL或LAC阳性组比较,差异有统计学意义(P<0.01);和抗β2-GPI抗体或LAC阳性组比较,差异有统计学意义(P<0.05)。结论:(1)ACL、抗β2-GPI抗体和LAC均与RSA有关。(2)ACL和抗β2-GPI抗体联合检测可以提高RSA患者抗磷脂抗体综合症检出率,对于临床诊断和指导治疗有重要意义。
Objective To investigate the clinical value of co-measurement of anticardiolipin（ACL）,anti-beta2-glycoprotein I,and lupus anticoagulant antibody（LAC） antibodies in women with recurrent spontaneous abortion（RSA）.Methods Levels of ACL,anti-beta2-glycoprotein I and LAC antibodies in 85 women with RSA（RSA group） and 50 normal multigravidas（control group） were detected.Results The positive rates of ACL,anti-beta2-glycoprotein I and LAC antibodies in RSA group and control group were 27.06%（23/85）,21.18%（18/85）,21.18%（18/85） and 8%（4/50）,2%（1/50）,6%（3/50）,respectively;And the differences between the two groups were significant（P 〈 0.01,P 〈 0.01,P 〈 0.05）.The positive rate of ACL or anti-beta2-glycoprotein I antibodies was 95.00%（38/40） in 40 women who were definitely diagnosed with antiphosphlipid syndrome（APS）,which was statistically different with that of ACL or LAC（P 〈 0.01） and that of LAC or anti-beta2-glycoprotein I antibody（P 〈 0.05）.Conclusions ACL,anti-beta2-glycoprotein I and LAC antibodies were related to RSA.The co-measurement of ACL and anti-beta2-glycoprotein I antibodies might increase the positive rate in screening APS in RSA patients.
出处
《实用医学杂志》
CAS
北大核心
2012年第20期3392-3394,共3页
The Journal of Practical Medicine
基金
温州市科技局科技计划项目基金资助(编号:Y20110235)
关键词
复发性流产
抗心磷脂抗体
抗β2-糖蛋白1抗体
狼疮抗凝物
Recurrent spontaneous abortion
Anticardiolipin antibody
Anti-beta2-glycoproteinI antibody
Lupus anticoagulant antibody
